Mallinckrodt (NYSE:MNK) announces positive findings from a large retrospective study of Acthar Gel in the treatment of the respiratory disease symptomatic sarcoidosis.
The company says analysis of a test of 302 patients showed that the use of Acthar Gel was associated with improved overall health status in 95% of patients as reported by physicians’ assessments, with more than half of patients (54%) seeing improvements in two or more symptoms.
Acthar Gel is approved by the FDA for the treatment of symptomatic sarcoidosis.
MNK +3.05% premarket to $3.72.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.